scispace - formally typeset
Search or ask a question
Institution

Purdue Pharma

CompanyPickering, Ontario, Canada
About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..


Papers
More filters
Patent
Laykea Tafesse1
25 Apr 2008
TL;DR: In this paper, the authors proposed a method for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA or a pharmaceutically acceptable derivative thereof.
Abstract: The invention relates to compounds of formula IA″ and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of formula IA″ or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of formula IA″ or a pharmaceutically acceptable derivative thereof.
Journal ArticleDOI
TL;DR: The octahydrobenzimidazol-2-ones 14 and 23 as mentioned in this paper showed excellent antagonistic activity towards both N/OFQ and mu receptors with high affinity.
Abstract: Small molecule N/OFQ receptor antagonists were designed and synthesized to further investigate the therapeutic potential of N/OFQ receptor modulators. The resulting octahydrobenzimidazol-2-ones 14 and 23 show excellent antagonistic activity towards both N/OFQ and mu receptors with high affinity to the human N/OFQ receptor.
Patent
25 Jan 2018
TL;DR: In this paper, C-terminal modified Protoxin II peptides that selectively inhibit the Nav1.7 sodium channel were used for prophylactic or therapeutic treatment of a disorder responsive to the blockade of sodium ion channels.
Abstract: The present invention relates to C-terminal modified Protoxin II peptides that selectively inhibit the Nav1.7 sodium channel; the present invention also relates to pharmaceutical compositions useful for prophylactic or therapeutic treatment of a disorder responsive to the blockade of sodium ion channels, especially Nav1.7 sodium ion channels; the present invention further provides methods of treating a disorder responsive to the blockade of sodium channels, and particularly Nav1.7 sodium channels, in a mammal suffering from excess activity of said channels.
Book ChapterDOI
01 Jan 2013
TL;DR: The mental status examination (MSE) is a set of processes that systematically examine various aspects of a person’s mental functioning – in essence, a physical examination of the mind.
Abstract: The mental status examination (MSE) is just that – a set of processes that systematically examine various aspects of a person’s mental functioning – in essence, a physical examination of the mind. A complete MSE constitutes a distinct portion of a complete psychiatric assessment. In practice, whether in psychiatry or other specialties, the MSE can be less comprehensive than a complete MSE, according to the clinical setting. MSEs can be partial – focusing only a particular aspect, such as mood or intelligence, or can be exhaustive.

Authors

Showing all 622 results

Network Information
Related Institutions (5)
Eli Lilly and Company
22.8K papers, 946.7K citations

87% related

Pfizer
37.4K papers, 1.6M citations

86% related

AstraZeneca
23.4K papers, 938.2K citations

84% related

GlaxoSmithKline
21.1K papers, 1.1M citations

83% related

Novartis
50.5K papers, 1.9M citations

83% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20218
202013
201915
201819
201750
201640